title: OY-TES-1 expression and serum immunoreactivity in epithelial ovarian cancer.
abstract: OY-TES-1 is a novel target that belongs to the family of 'cancer/testis' (CT) antigens. Our goal was to examine the expression and immunogenicity of OY-TES-1 in epithelial ovarian cancer (EOC) to determine its potential as a target for vaccine therapy. OY-TES-1 expression was determined by one-step reverse transcriptase PCR on 100 EOC samples, 5 EOC cell lines, and a panel of normal tissues. Immunohistochemistry (IHC) was performed on the same panel of EOC tissues. Sera from a sub-group of patients were tested for OY-TES-1 antibody by ELISA. Thymus and leukocytes were weakly positive for OY-TES-1 while the remaining 5 normal tissues were negative. Expression of OY-TES-1 by either RT-PCR and/or IHC was demonstrable in 69/100 (69%) tumors. Humoral immunity to OY-TES-1 was demonstrated in 1/10 (10%) serum samples from patients whose tumors expressed the antigen. The median follow-up of the patient population was 34 months. There was no correlation between antigen expression and stage, grade, histology and survival. OY-TES-1 is expressed in 69% of patients with EOC, is absent from normal ovarian tissue, and a proportion of patients show evidence of a specific humoral immune response. These findings make OY-TES-1 an attractive target for antigen-specific immunotherapy in EOC.
authors.affiliation: Department of Gynecologic Oncology, Roswell Park Cancer Institute Buffalo, NY 14263, USA.
authors.forename: Jonathan
authors.initials: J
authors.lastname: Tammela
authors.forename: Akiko
authors.initials: A
authors.lastname: Uenaka
authors.forename: Toshiro
authors.initials: T
authors.lastname: Ono
authors.forename: Yuji
authors.initials: Y
authors.lastname: Noguchi
authors.forename: Achim A
authors.initials: AA
authors.lastname: Jungbluth
authors.forename: Paulette
authors.initials: P
authors.lastname: Mhawech-Fauceglia
authors.forename: Feng
authors.initials: F
authors.lastname: Qian
authors.forename: Sally
authors.initials: S
authors.lastname: Schneider
authors.forename: Sameer
authors.initials: S
authors.lastname: Sharma
authors.forename: Deborah
authors.initials: D
authors.lastname: Driscoll
authors.forename: Shashikant
authors.initials: S
authors.lastname: Lele
authors.forename: Lloyd J
authors.initials: LJ
authors.lastname: Old
authors.forename: Eiichi
authors.initials: E
authors.lastname: Nakayama
authors.forename: Kunle
authors.initials: K
authors.lastname: Odunsi
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology; D000912:Antibodies, Neoplasm / Q000097:blood*; D002277:Carcinoma / Q000737:chemistry / Q000378:metabolism* / Q000473:pathology; D002352:Carrier Proteins / Q000032:analysis / Q000235:genetics / Q000378:metabolism*; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D007962:Leukocytes / Q000737:chemistry; D051379:Mice; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000737:chemistry / Q000378:metabolism* / Q000473:pathology; D012333:RNA, Messenger / Q000032:analysis / Q000378:metabolism; D013950:Thymus Gland / Q000737:chemistry
chemical_list: C485651:ACRBP protein, human; D000911:Antibodies, Monoclonal; D000912:Antibodies, Neoplasm; D002352:Carrier Proteins; D012333:RNA, Messenger